



MTTI forms Partnership with North China Pharmaceutical Company

West Chester, PA. September 18, 2003. Molecular Targeting Technologies, Inc. announced today it has signed an agreement with the North China Pharmaceutical Group Corporation (NCPC) to develop a human anti-rabies monoclonal antibody product in China for post-exposure treatment of rabies.

Rabies is a worldwide public health problem. Human deaths due to rabies are estimated between 40,000 and 100,000 per year worldwide and millions of persons undergo post-exposure prophylaxis, primarily in developing countries.

"The monoclonal antibody (Mab) product will consist of a mixture of human anti-rabies Mab's that have been shown to neutralize a wide range of rabies virus strains and that are active in animal efficacy models," said Dr. Chris Pak, President & CEO of MTTI. "This product is intended to replace the currently used horse and human rabies immune globulin products that are in short supply in many countries."

Successful development of the human anti-rabies Mab product will yield a product that not only has a better safety and efficacy profile than the currently used immune globulin products, but will also be readily produced via conventional mass culture technology to alleviate the supply shortage of rabies immune globulin.

Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties, which may cause actual results to differ materially from the statements made. Such factors include, but are not limited to, changing market conditions, clinical trial results, the establishment of new corporate alliances, the impact of competitive products and pricing, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time-to-time in the Company's filings with the authorities

Contact: Jeffrey Mattis, PhD, jmattis@mtarget.com, 610.738.7938